FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310706084> ?p ?o ?g. }

• W4310706084 endingPage "101769" @default.
• W4310706084 startingPage "101769" @default.
• W4310706084 abstract "Cytomegalovirus (CMV) infection significantly impacts the morbidity and mortality of patients undergoing allogeneic hematopoietic stem cell transplant (HSCT). Despite monitoring and pharmacologic prophylaxis with drugs such as valganciclovir or ganciclovir, rates of early CMV reactivation have continually persisted, contributing to increased rates of morbidity and mortality in allogeneic-HSCT patients. This study evaluates the outcomes of letermovir in preventing CMV reactivation and CMV-related complications in HSCT recipients with initiation of therapy at +21 days in high-risk patients.We retrospectively analyzed adult patients at University of Southern California (USC) Norris Cancer Hospital who received allogeneic-HSCT from 2018 to 2020 with subsequent serial CMV monitoring and treatment. CMV reactivation was determined in patients if they had clinically significant serum CMV viremia (viremia requiring treatment) or organ involvement by day+100. Primary endpoint assessed was day+100 rates of CMV reactivation. Secondary end-points included 1-year OS, 1-year RFS, and incidence of GVHD. Descriptive statistics were used to compare characteristics between groups used in this study, with a significance level of α = 0.05.Between 2018 and 2020, 116 adult HSCT recipients were reviewed. 51% were male and 49% were female; donor sources consisted of 27% match related donor (MRD) 28% match-unrelated donor (MUD), and 45% haploidentical donor. Of the 116 patients, 92 were identified as high-risk for CMV reactivation. 71 patients received letermovir prophylaxis, and 21 patients received no prophylaxis. In high-risk patients, after adjusting for GVHD status and transplant type, patients that received letermovir had no statistically significant difference of having D + 100 CMV reactivation compared to patients that did not receive letermovir. 1.02 (95% CI: 0.35, 3.20) (p = 0.97). Moreover, there were no statistically significant difference observed between letermovir treatment and 1-year OS, 1-year RFS, and incidence of GVHD.Patients in the high-risk letermovir group had outcomes that were comparable to the lower risk non-letermovir group. There was no significant difference in CMV D + 100 reactivation between high-risk patients who did not receive letermovir compared to the patients who did. While other studies have shown that early initiation of letermovir may be associated with improved outcomes, our study shows that the use of letermovir with initiation at 21 days may not necessarily translate to improved secondary outcomes such as overall survival. Further prospective studies evaluating the time of initiating therapy and outcomes are needed." @default.
• W4310706084 created "2022-12-16" @default.
• W4310706084 creator A5000191195 @default.
• W4310706084 creator A5014270597 @default.
• W4310706084 creator A5028688332 @default.
• W4310706084 creator A5033933115 @default.
• W4310706084 creator A5034412477 @default.
• W4310706084 creator A5044020999 @default.
• W4310706084 creator A5044693215 @default.
• W4310706084 creator A5069986166 @default.
• W4310706084 creator A5079190934 @default.
• W4310706084 creator A5080569233 @default.
• W4310706084 creator A5082565023 @default.
• W4310706084 creator A5086668610 @default.
• W4310706084 date "2023-02-01" @default.
• W4310706084 modified "2023-10-01" @default.
• W4310706084 title "Real world experience: Examining outcomes using letermovir for CMV prophylaxis in high-risk allogeneic hematopoietic stem cell patients in the setting of using T-cell depletion as GVHD prophylaxis" @default.
• W4310706084 cites W1973646541 @default.
• W4310706084 cites W2095186947 @default.
• W4310706084 cites W2108928565 @default.
• W4310706084 cites W2119393764 @default.
• W4310706084 cites W2147980413 @default.
• W4310706084 cites W2165903332 @default.
• W4310706084 cites W2315851568 @default.
• W4310706084 cites W2395266396 @default.
• W4310706084 cites W2771598353 @default.
• W4310706084 cites W2913669888 @default.
• W4310706084 cites W2948118452 @default.
• W4310706084 cites W2984122424 @default.
• W4310706084 cites W3092010118 @default.
• W4310706084 cites W3097497565 @default.
• W4310706084 cites W3106719546 @default.
• W4310706084 cites W3135137897 @default.
• W4310706084 cites W3213596607 @default.
• W4310706084 cites W3214901906 @default.
• W4310706084 doi "https://doi.org/10.1016/j.trim.2022.101769" @default.
• W4310706084 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36464218" @default.
• W4310706084 hasPublicationYear "2023" @default.
• W4310706084 type Work @default.
• W4310706084 citedByCount "3" @default.
• W4310706084 countsByYear W43107060842023 @default.
• W4310706084 crossrefType "journal-article" @default.
• W4310706084 hasAuthorship W4310706084A5000191195 @default.
• W4310706084 hasAuthorship W4310706084A5014270597 @default.
• W4310706084 hasAuthorship W4310706084A5028688332 @default.
• W4310706084 hasAuthorship W4310706084A5033933115 @default.
• W4310706084 hasAuthorship W4310706084A5034412477 @default.
• W4310706084 hasAuthorship W4310706084A5044020999 @default.
• W4310706084 hasAuthorship W4310706084A5044693215 @default.
• W4310706084 hasAuthorship W4310706084A5069986166 @default.
• W4310706084 hasAuthorship W4310706084A5079190934 @default.
• W4310706084 hasAuthorship W4310706084A5080569233 @default.
• W4310706084 hasAuthorship W4310706084A5082565023 @default.
• W4310706084 hasAuthorship W4310706084A5086668610 @default.
• W4310706084 hasConcept C120665830 @default.
• W4310706084 hasConcept C121332964 @default.
• W4310706084 hasConcept C126322002 @default.
• W4310706084 hasConcept C203014093 @default.
• W4310706084 hasConcept C203092338 @default.
• W4310706084 hasConcept C2522874641 @default.
• W4310706084 hasConcept C2776185481 @default.
• W4310706084 hasConcept C2776317777 @default.
• W4310706084 hasConcept C2776409557 @default.
• W4310706084 hasConcept C2777408962 @default.
• W4310706084 hasConcept C2777732132 @default.
• W4310706084 hasConcept C2777965375 @default.
• W4310706084 hasConcept C2779820661 @default.
• W4310706084 hasConcept C2780727368 @default.
• W4310706084 hasConcept C2911091166 @default.
• W4310706084 hasConcept C3013748606 @default.
• W4310706084 hasConcept C535046627 @default.
• W4310706084 hasConcept C61511704 @default.
• W4310706084 hasConcept C71924100 @default.
• W4310706084 hasConceptScore W4310706084C120665830 @default.
• W4310706084 hasConceptScore W4310706084C121332964 @default.
• W4310706084 hasConceptScore W4310706084C126322002 @default.
• W4310706084 hasConceptScore W4310706084C203014093 @default.
• W4310706084 hasConceptScore W4310706084C203092338 @default.
• W4310706084 hasConceptScore W4310706084C2522874641 @default.
• W4310706084 hasConceptScore W4310706084C2776185481 @default.
• W4310706084 hasConceptScore W4310706084C2776317777 @default.
• W4310706084 hasConceptScore W4310706084C2776409557 @default.
• W4310706084 hasConceptScore W4310706084C2777408962 @default.
• W4310706084 hasConceptScore W4310706084C2777732132 @default.
• W4310706084 hasConceptScore W4310706084C2777965375 @default.
• W4310706084 hasConceptScore W4310706084C2779820661 @default.
• W4310706084 hasConceptScore W4310706084C2780727368 @default.
• W4310706084 hasConceptScore W4310706084C2911091166 @default.
• W4310706084 hasConceptScore W4310706084C3013748606 @default.
• W4310706084 hasConceptScore W4310706084C535046627 @default.
• W4310706084 hasConceptScore W4310706084C61511704 @default.
• W4310706084 hasConceptScore W4310706084C71924100 @default.
• W4310706084 hasLocation W43107060841 @default.
• W4310706084 hasLocation W43107060842 @default.
• W4310706084 hasOpenAccess W4310706084 @default.
• W4310706084 hasPrimaryLocation W43107060841 @default.
• W4310706084 hasRelatedWork W1996182916 @default.
• W4310706084 hasRelatedWork W2027173317 @default.

• next